二代测序技术用于慢性淋巴细胞白血病患者免疫球蛋白可变区特征及其预后意义的研究
研究纳入2018年12月至2023年5月江苏省人民医院初诊的36例慢性淋巴细胞白血病患者,采用二代测序检测免疫球蛋白重链与轻链基因重排,分析其基因特征及预后价值。结果显示二代测序与Sanger测序一致性较好,IGHV突变状态、IGLV3-21使用及IGHV无突变双克隆与预后相关。
要点
- 二代测序检测IGHV与Sanger测序一致性好(r=0.957,P<0.001)。
- BCR同型模式IGHV #8/8B亚组更易发生Richter转化(72.7%对16.0%,P=0.002)。
- IGHV无突变的双克隆可能提示预后不良。
核心结论
- 二代测序检测IG基因重排可分析IGHV突变状态、优势克隆及预后价值,并可研究IGK/IGL基因重排片段及亚克隆使用情况。
- IGLV3-21 CLL的不良预后研究提供了线索,IGHV无突变的双克隆可能提示预后不良。
研究设计与样本
- 采集2018年12月至2023年5月在江苏省人民医院初诊的36例CLL患者血液和(或)骨髓样本,包括12例BCR同型模式患者。
- 应用二代测序技术检测IGH、IGK、IGL基因重排,研究IG基因特点及预后价值。
主要发现
- 二代测序检测IGHV与Sanger测序具有明显相关性和较好一致性(r=0.957,P<0.001)。
- 36例患者中9例(25.0%)IGHV有突变、27例(75.0%)IGHV无突变。
- MYD88突变在IGHV有突变患者中发生率更高[1/27(3.7%)对4/9(44.4%),P=0.009]。
- BCR同型模式IGHV #8/8B亚组患者的+12发生率更高[4/11(36.4%)对1/25(4.0%),P=0.023],并更易发生Richter转化[8/11(72.7%)对4/25(16.0%),P=0.002]。
- 使用和非使用IGLV3-21基因片段患者的中位TTFT分别为5.2(1.1~41.5)个月和9.9(0.1~94.4)个月。
关键数值与推荐
- 36例患者使用IGKV(36/36,100%),15例使用IGLV(15/36,41.7%),其中IGLV3-21(5/15,33.3%)使用率最高。
- 使用IGLV3-21患者均为Binet C分期及Rai Ⅲ~Ⅳ期,del(13)(q14)发生率为60.0%(3/5)。
- 以2.5%的总检测片段条数为IGHV亚克隆阈值时,检测出4例(4/36,11.1%)样本具有2个功能性克隆。
- 有突变单克隆组(8/36,22.2%)和有突变双克隆组(1/36,2.8%)中位TTFT分别为2.8(0.9~72.7)个月和12.8个月,中位OS期分别为57.5(32.0~120.7)个月和51.8个月。
- 无突变单克隆组(24/36,66.7%)和无突变双克隆组(2/36,5.6%)中位TTFT分别为10.9(0.3~94.4)个月和6.3(0.1~12.5)个月,中位OS期分别为49.9(22.2~211.1)个月和30.0(9.6~50.3)个月(P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To elucidate the genomic characteristics of the immunoglobulin (IG) heavy-chain variable region and light-chain variable region, the expression of subclones, and the prognostic significance in patients with CLL. Methods: Blood and/or bone marrow specimens were gathered from a cohort of 36 patients with CLL diagnosed at Jiangsu Province Hospital from December 2018 to May 2023, including 12 cases of B cell receptor (BCR) stereotyped patients. IG heavy-chain (IGH) and light-chain (IG Kappa [IGK] and IG lambda [IGL]) gene rearrangements were performed using next-generation sequencing (NGS) technology to analyze the characteristics and prognostic value in CLL. Results: NGS detection of IG variable region (IGHV) demonstrated a significant correlation and superior consistency with Sanger sequencing (r=0.957, P < 0.001). Among the 36 patients, the IGH variant (IGHV) was observed in 9 (25.0%) but not in 27 (75.0%) participants. The incidence of the MYD88 mutation was higher among patients with mutated IGHV [1/27 (3.7%) vs 4/9 (44.4%), P=0.00]. A high incidence of trisomy 12 was observed in the IGHV #8/#8B subset [4/11 (36.4%) vs 1/25 (4.0%), P=0.023], which were more likely to develop Richter transformation [8/11 (72.7%) vs 4/25 (16.0%), P=0.002]. In the patient cohort, 36 individuals (36/36, 100.0%) used the IGK variable, whereas 15 individuals (15/36, 41.7%) employed the IGL variable (IGLV). IGLV3 - 21 reported the highest utilization rate in IGLV (5/15, 33.3%). Remarkably, patients with CLL with IGLV3-21 fragments were exclusively observed in the Binet C stage and Rai Phase Ⅲ-Ⅳ, with an incidence of del (13) (q14) at 60.0% (3/5). The median time to first treatment (TTFT) of patients with or without IGLV3 - 21 fragments was 5.2 (1.1 - 41.5) and 9.9 (0.1 - 94.4) months, respectively. Using the total reads threshold of 2.5%, 4 (4/36, 11.1%) samples were detected to have two IGHV productive clones. The median TTFT and overall survival (OS) time were 2.8 (0.9-72.7) and 12.8 months in patients with one mutated clone and 57.5 (32.0-120.7) and 51.8 months in those with two mutated clones, respectively. The median TTFT and OS time were 10.9 (0.3-94.4) and 6.3 (0.1 - 12.5) months in patients with one unmutated clone and 49.9 (22.2 - 211.1) and 30.0 (9.6 - 50.3) months in those with multiple unmutated clones, respectively (P>0.05) . Conclusions: Detection of IG gene rearrangements using NGS technology not only facilitates the analysis of the IGHV mutation status, dominant clones, and prognostic value but also contributes to the exploration of IGK/IGL gene rearrangement fragments and the utilization of subclones. Further, it provides information about the poor prognosis of IGLV3 - 21 CLL. The shortened survival of the two unmutated clone groups in the IGHV unmutated group may indicate a poor prognosis. 目的: 利用二代测序(NGS)技术分析慢性淋巴细胞白血病(CLL)患者免疫球蛋白(IG)重链和轻链可变区基因特征、亚克隆情况及预后价值。 方法: 采集2018年12月到2023年5月在江苏省人民医院初诊的36例CLL患者[包括12例B细胞受体(BCR)同型模式患者]的血液和(或)骨髓样本,应用NGS技术检测免疫球蛋白重链(IGH)、轻链(IGK、IGL)基因重排,研究IG基因在CLL中的特点及预后价值。 结果: NGS检测IG重链可变区(IGHV)与Sanger测序具有明显的相关性和较好的一致性(r=0.957,P<0.001)。36例患者中,9例(25.0%)患者IGHV有突变、27例(75.0%)患者IGHV无突变。MYD88突变在IGHV有突变患者中发生率更高[1/27(3.7%)对4/9(44.4%),P=0.009]。BCR同型模式IGHV #8/8B亚组患者的12号染色体三体(+12)[4/11(36.4%)对1/25(4.0%),P=0.023]的发生率更高,并更易发生Richter转化[8/11(72.7%)对4/25(16.0%),P=0.002]。36例患者使用IGKV(36/36,100%);15例使用IGLV(15/36,41.7%),其中IGLV3-21(5/15,33.3%)的使用率最高:患者均为Binet C分期及Rai Ⅲ~Ⅳ期,del(13)(q14)的发生率为60.0%(3/5)。使用和非使用IGLV3-21基因片段患者的中位至首次治疗时间(TTFT)分别为5.2(1.1~41.5)个月和9.9(0.1~94.4)个月。当定义2.5%的总检测片段条数(total reads)为IGHV亚克隆阈值时,检测出4例(4/36,11.1%)样本具有2个功能性克隆。有突变单克隆组(8/36,22.2%)和有突变双克隆组(1/36,2.8%)患者的中位TTFT分别为2.8(0.9~72.7)个月和12.8个月,中位总生存(OS)期分别为57.5(32.0~120.7)个月和51.8个月;无突变单克隆组(24/36,66.7%)和无突变双克隆组(2/36,5.6%)患者的中位TTFT分别为10.9(0.3~94.4)个月和6.3(0.1~12.5)个月,中位OS期分别为49.9(22.2~211.1)个月和30.0(9.6~50.3)个月(P>0.05)。 结论: 应用NGS技术检测IG基因重排,不仅能分析IGHV的突变状态、优势克隆、判断预后,还能够研究IGK/IGL的基因重排片段及亚克隆的使用情况,为IGLV3-21 CLL的不良预后研究提供了线索。IGHV无突变的双克隆可能提示预后不良。.
引用
- Guo Z, Jin HM, Qiu TL, et al. [Application of next-generation sequencing technology for the investigation of immunoglobulin variable region characteristics and their prognostic significance in patients with chronic lymphocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40355356. doi:10.3760/cma.j.cn121090-20240819-00310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。